New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Palisade Bio, Inc.

Contributing Author

Recent Articles by Palisade Bio, Inc.

Sep-17	Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data PALI GlobeNewswire
Sep-05	Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) PALI GlobeNewswire
Aug-25	Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 PALI GlobeNewswire
Aug-07	Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 PALI GlobeNewswire
Jul-31	Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China PALI GlobeNewswire
Jul-23	Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million PALI GlobeNewswire
Jul-22	Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference PALI GlobeNewswire
Jul-09	Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors PALI GlobeNewswire
May-27	Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis PALI GlobeNewswire
May-06	Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases PALI GlobeNewswire
May-01	Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit PALI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.